Since its first draft, the GPP guidelines have been adopted and used in HIV research and far beyond. AVAC has collected this body of evidence for GPP to demonstrate the power of GPP, to show how GPP can be measured and replicated, and to offer GPP training, tools and connection to everyone involved in the research enterprise. Visit here.
GPP Body of Evidence
A clearinghouse of case studies and analyses demonstrating the power of GPP
Announcing the Good Participatory Practice Body of Evidence
We are thrilled to announce the Good Participatory Practice (GPP) Body of Evidence, a new online clearinghouse of case studies and analyses demonstrating the power of GPP, along with tools, templates and trainings for GPP implementation. The resources we’ve gathered for this much-needed “one-stop GPP shop” can be used to show the impact of GPP to date, how it can be measured going forward, and its practical application in real-time.
The Good Participatory Practice Guidelines have been shaping and improving HIV prevention research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.
Over the past 16 years, the original GPP guidelines for HIV prevention have been issued in 10 languages and adapted to other disease areas, including tuberculosis, COVID-19, and emerging pathogens. GPP has given rise to a robust global community of practice, with an expansive history of lessons learned and success stories for the world to build upon.
But GPP implementation is far from easy. Because GPP looks different in every context and outcomes can be difficult to quantify, engagement work is often seen as secondary to clinical processes, and therefore undervalued and under-resourced. The GPP Body of Evidence demonstrates the contribution of GPP to the research enterprise, and the professionalization of GPP implementation.
Rest assured that this is not a one-off effort! Stay tuned for a webinar series in 2024 with key partners including WHO and Wellcome Trust that will highlight critical issues in stakeholder engagement in research, linking to corresponding resources from the Body of Evidence. And we’ll be keeping the Body of Evidence up to date – so please reach out if you have resources to add.
It’s time for GPP to become an international standard for clinical research. Making that case and making it happen, using the GPP Body of Evidence, has never been easier.
FAPP Letter: Vote NO on House L-HHS Bill to Continue Progress Against HIV/AIDS
The FAPP AIDS Budget and Appropriations Coalition (ABAC) wrote letter urging Members of Congress to vote no on the House L-HHS Appropriations Bill (H.R. 5894), which includes $767 million in cuts and eliminations of domestic HIV programs.The letter also urges members to vote down two amendments which would eliminate funding for the Minority HIV/AIDS Fund and cut NIAID funding.
Avac Event
African Civil Society Mobilization for PEPFAR Reauthorization
Tuesday, November 28 at 7:00 AM ET
Moderator: Richard Muko, Regional Implementation Advocacy Manager, AVAC
Panelists: Joan Chamungu, Tanzanian Network of Women Living with HIV, Lawrence Khonyongwa, Malawi Network of People of Living with HIV, TBC, African Network of Youth Living with HIV, Annette Gaudino, Advocacy Coalition Manager, GAPP
Hosted by African Network of Youth Living with HIV (AY+), East African Network of AIDS Serving Organizations (EANNASO), Key Populations Trans-National Collaboration (KPTNC) and Coalition to build Momentum, Power, Activism, Strategy & Solidarity (COMPASS)
Join civil society organizations in PEPFAR recipient countries to discuss the status and political context of the current reauthorization and mobilize to call on the US Congress to recommit this life sustaining program. Bring your questions and please share this invitation widely in your relevant networks.
Results from STI Landscaping Analyses in East and Southern Africa—Parts 1 and 2
Hear results from STI landscaping projects conducted in seven different countries from East and Southern Africa that explored needs for STI vaccines and diagnostics.
Part 1 Recording / Part 2 Recording
Latu Human Rights Foundation Slides / ACTS 101 Uganda Slides / Journalists Association Against AIDS (JournAIDS) Slides/ Lesotho Network of AIDS Service Organizations (LENASO) Slides / HIV Survivors and Partners Network (HIVSPN) Slides / Pangaea Zimbabwe AIDS Trust (PZAT) Slides / Nyanza Reproductive Health Society (NRHS) Slides
Avac Event
Sex, Gender & HIV Cure Research
Wednesday, December 6, 1:00 to 2:00 PM ET
This webinar reviewed core concepts discussed in the previous webinar, Let’s Talk About HIV Cure Research: An Introduction to the science under investigation and introduce how hormones may impact cure strategies.
This webinar featured Dr. Jessica Prodger of Western University.
Objectives:
- Review key concepts and terminology of HIV cure
- Known sex differences of HIV progression
- Potential impact of hormones on HIV cure strategies
Recording
Avac Event
Let’s Talk About HIV Cure Research: An Introduction to the science under investigation
Wednesday, November 15, 11:00 to 12:30 PM ET
Dr. Marina Caskey of Rockefeller University and members of the REACH Community Advisory Board hosted a webinar on November 15 to review the current state of HIV cure research. This webinar explored what makes curing HIV so challenging, the strategies being pursued, and what is happening in locally in NYC!
New Episode of the Px Pulse Podcast
The intersection of HIV research and pregnancy
AVAC’s Px Pulse podcast has a new episode: Inclusion of Pregnant and Lactating People in HIV Research: What you need to know.
People who are pregnant or lactating (PLP) have historically been excluded from research because of concerns for the developing fetus. But this has led to a dearth of data on new interventions against health threats for this population. In the case of HIV, pregnancy raises the risk of acquiring HIV by up to three times, but providers often do not have the data to know whether a new intervention is safe or how it will work for pregnant patients. As a result, PLP and their physicians are left to make difficult decisions around the use of proven HIV prevention products as they await more data specific to pregnancy and lactation.
But change is in the air. Champions for the inclusion of PLP in research are paving the way for a paradigm shift— one that will redefine this population from needing protection from research to being better protected through research. In this episode of Px Pulse, AVAC’s Manju Chatani-Gada takes us through conversations with a trial participant who became pregnant, researchers, policy-makers and donors to understand why this population gets excluded, the impact it has, and what to do about it.
Tune in to hear
- Dr. Anne Drapkin Lyerly, Principal Investigator of the PHASES Project to advance equitable inclusion of pregnant women in HIV research and its follow-on project, PREPARE, focused on ethical HIV research in adolescents who are pregnant.
- Elisia Madende, Trial participant in the HPTN 084 trial in Zimbabwe
- Dr. Ashley Lima, Health Science Specialist and Lead Technical Advisor for Socio-behavioral Research – USAID Office of HIV/AIDS Research Division
- Dr. Takunda Sola, HIV Prevention and Key Populations Medical Officer- Zimbabwe MoH AIDS/TB Unit
Advocacy resources
- Report: Advancing HIV Prevention Research in PLP: Think Tank Report & Action Plan
- Advocates Guide: An Advocate’s Guide to Research in Pregnant and Lactating Populations
- Factsheet: Including Pregnant and Lactating Populations in HIV Prevention Research
- Infographic: Pregnant and Lactating People (PLP) in Ongoing HIV Prevention Trials
- Webinar: More than Vessels: Pregnant people deserve inclusion in HIV prevention research
- Guidance: PHASES guidance: Ending the evidence gap for pregnant women around HIV & co-infections
- Meeting Report: Call to Accelerate the Study of New Drugs for HIV in Pregnant and Breastfeeding Women
- JIAS Special Issue: Approaches to Enhance and Accelerate Investigation of New HIV Drugs in Pregnancy
Frontiers in Reproductive Health: How might we motivate uptake of the Dual Prevention Pill?
Findings from human-centered design research with potential end users, male partners and healthcare providers
AVAC’s Wawira Nyagah and Kate Segal co-authored a comprehensive manuscript on a demand generation approach for the DPP (Dual Prevention Pill) including findings from research with potential users, male partners, and healthcare providers.
Read the abstract below and the full published research article here.
Multipurpose prevention technologies (MPTs) combining contraception with HIV prevention offer a promising solution to uptake and adherence challenges faced with oral pre-exposure prophylaxis (PrEP). The Dual Prevention Pill (DPP), which combines oral PrEP with an oral contraceptive pill (OCP), could address unmet need for family planning (FP) and HIV prevention. This study aimed to identify barriers and motivators for DPP uptake to inform the development of a DPP demand generation strategy and broader introduction efforts for MPTs.
Civil Society Analysis: Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (WHO Pandemic Agreement)
This analysis is a compilation of recommendations from civil society and community organisations on the DRAFT Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response (WHO Pandemic Agreement).